Table of Contents

Recent Posts

The use of novel targeted therapies and immunotherapies is showing promise in ALL. These agents are achieving great responses not only in pediatric patients but also in adult patients with relapsed/refractory ALL.

Response is the key prognostic factor for long-term outcomes in patients with CML. In this ClinicalThought post, I discuss why early response matters and offer suggestions on managing patients without optimal responses.

The NCCN recently updated its guidelines for the use of chemotherapy in patients with bladder cancer. In this ClinicalThought, I explore which of these changes should definitely be applied in clinical practice and which I believe have only limited evidence to support them.

With additional treatment options for trastuzumab-resistant/refractory HER2-positive metastatic breast cancer, come new challenges in presenting their complexities to patients. In this post, I offer my perspective on framing the patient-centered discussion.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.